Vifor Pharma Ltd Overview
Pro stress-test →Vifor Pharma is now a subsidiary of CSL Limited following acquisition in August 2022. Operating as CSL Vifor, the company specializes in therapies for iron deficiency, nephrology, and cardio-renal diseases with a significant portfolio in chronic kidney disease management and anemia treatment.
Strategic Profile
Pro stress-test →Vifor Pharma operated as a specialty pharmaceutical company leveraging a joint venture with Fresenius Medical Care for nephrology products. The business focused on high-unmet-need therapeutic areas supported by in-licensing and strategic partnerships.
Competitive Landscape
Pro stress-test →As a CSL subsidiary, Vifor Pharma competes in nephrology, iron deficiency, and cardio-renal therapeutic areas. Prior to acquisition, key competitors included other specialty pharma companies and dialysis providers serving chronic kidney disease and anemia markets.
Industry Context
Vifor Pharma Ltd operates in Specialty Pharmaceuticals - Nephrology & Iron Deficiency Therapies.
Key facts
Founded: 2008 · Headquarters: Glattbrugg, Zurich, Switzerland · Employees: Approximately 2,600 at acquisition · Revenue: Estimated $1B+ at time of acquisition (2022) · Market cap: N/A (Acquired subsidiary)